Cargando…

Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience

SIMPLE SUMMARY: CAR T-cell therapies have undoubtedly revolutionized the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. These therapies represent a valuable new treatment option, yielding impressive complete remission rates and improving survival. The aim of this article is to give an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Casadei, Beatrice, Argnani, Lisa, Guadagnuolo, Serafina, Pellegrini, Cinzia, Stefoni, Vittorio, Broccoli, Alessandro, Nanni, Laura, Morigi, Alice, Lolli, Ginevra, Guarino, Maria, Spinardi, Luca, Pierucci, Elisabetta, Fanti, Stefano, Bartoletti, Michele, Dicataldo, Michele, Sabattini, Elena, Bonifazi, Francesca, Zinzani, Pier Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507677/ https://www.ncbi.nlm.nih.gov/pubmed/34638273 http://dx.doi.org/10.3390/cancers13194789

Ejemplares similares

Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients
por: Casadei, Beatrice, et al.
Publicado: (2020)

Effectiveness of chemotherapy after anti‐PD‐1 blockade failure for relapsed and refractory Hodgkin lymphoma
por: Casadei, Beatrice, et al.
Publicado: (2020)

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience
por: Stefoni, Vittorio, et al.
Publicado: (2022)

The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients
por: Broccoli, Alessandro, et al.
Publicado: (2017)

Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience
por: Broccoli, Alessandro, et al.
Publicado: (2021)

Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia
por: Broccoli, Alessandro, et al.
Publicado: (2021)

Impressive Continuous Complete Response after Mogamulizumab in a Heavily Pretreated Sézary Syndrome Patient
por: Lolli, Ginevra, et al.
Publicado: (2020)

A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report
por: Broccoli, Alessandro, et al.
Publicado: (2018)

BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia
por: Broccoli, Alessandro, et al.
Publicado: (2019)

First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi
por: Broccoli, A., et al.
Publicado: (2019)

Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia
por: Broccoli, Alessandro, et al.
Publicado: (2023)

90‐yttrium‐ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high‐risk follicular lymphoma: updated long‐term results after a median follow‐up of 7 years
por: Casadei, Beatrice, et al.
Publicado: (2016)

Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review
por: Pensato, Umberto, et al.
Publicado: (2022)

Correction to: Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review
por: Pensato, Umberto, et al.
Publicado: (2022)

ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study
por: Giladi, Odil, et al.
Publicado: (2022)

Poster: ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study
por: Giladi, Odil, et al.
Publicado: (2022)

High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience
por: Derenzini, Enrico, et al.
Publicado: (2015)

Management of central nervous system relapse in a young patient affected by primary mediastinal large B‐cell lymphoma: A case report
por: Marangon, Miriam, et al.
Publicado: (2020)

Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results
por: Stefoni, V, et al.
Publicado: (2016)

Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS
por: Stefoni, Vittorio, et al.
Publicado: (2020)

Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma
por: Broccoli, Alessandro, et al.
Publicado: (2020)

Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity
por: De Matteis, Serena, et al.
Publicado: (2023)

Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity
por: Pensato, Umberto, et al.
Publicado: (2021)

Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors
por: Argnani, Lisa, et al.
Publicado: (2022)

Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy
por: De Matteis, Serena, et al.
Publicado: (2022)

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma
por: Pellegrini, Cinzia, et al.
Publicado: (2017)

Evaluation of the Relapse Risk and Survival Rate in Patients with Hodgkin Lymphoma: A Monocentric Experience
por: Potre, Ovidiu, et al.
Publicado: (2021)

P1074: PRIMARY REFRACTORY HODGKIN’S LYMPHOMA: A MOROCCAN MONOCENTRIC RETROSPECTIVE STUDY
por: Ababou, M., et al.
Publicado: (2022)

Methodological framework for radiomics applications in Hodgkin’s lymphoma
por: Sollini, Martina, et al.
Publicado: (2020)

The relevance of a low JAK2(V617F) allele burden in clinical practice: a monocentric study
por: Perricone, Margherita, et al.
Publicado: (2017)

Immune Microenvironment Features and Dynamics in Hodgkin Lymphoma
por: Bertuzzi, Clara, et al.
Publicado: (2021)

Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study
por: Casadei, Beatrice, et al.
Publicado: (2022)

A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia
por: Broccoli, Alessandro, et al.
Publicado: (2022)

Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
por: Argnani, Lisa, et al.
Publicado: (2022)

P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE
por: Rusconi, Chiara, et al.
Publicado: (2023)

Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients
por: Zinzani, P L, et al.
Publicado: (2004)

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
por: Tarantelli, Chiara, et al.
Publicado: (2021)

Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma
por: Broccoli, Alessandro, et al.
Publicado: (2018)

PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE
por: Di Folca, S., et al.
Publicado: (2022)

Intraventricular Meningiomas: Clinical-Pathological and Genetic Features of a Monocentric Series
por: Ammendola, Serena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vhne8400uk1u2ra8dpv64nbcc0